A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study

被引：0
|
作者：
Wedzicha, Jadwiga A. [1 ]
Decramer, Marc [2 ]
Vestbo, Jorgen [3 ]
Gallagher, Nicola [4 ]
Kim, Han-Joo [5 ]
McBryan, Danny [6 ]
Banerji, Donald [5 ]
机构：
[1] UCL, Dept Acad Resp Med, London, England
[2] Univ Leuven, Univ Hosp, Div Resp, Leuven, Belgium
[3] Manchester Acad Hlth Sci Ctr, Resp Res Grp, Manchester, Lancs, England
[4] Novartis Horsham Res Ctr, Primary Care, Horsham, W Sussex, England
[5] Novartis Pharmaceut, Primary Care, E Hanover, NJ USA
[6] Novartis Pharma AG, Primary Care, Basel, Switzerland
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
COPD; -; management; Bronchodilators; Exacerbation;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2208
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Novel Study Design for the Comparison Between Once-Daily QVA149 and Twice-Daily Salmeterol/Fluticasone on the Reduction of COPD Exacerbations: The FLAME Study
    Wedzicha, Jadwiga
    Vestbo, Jorgen
    Gallagher, Nicola
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [2] A NOVEL STUDY DESIGN FOR THE COMPARISON BETWEEN ONCE-DAILY QVA149 AND TWICE-DAILY SALMETEROL/FLUTICASONE ON THE REDUCTION OF COPD EXACERBATIONS: THE FLAME STUDY
    Kwaijtaal, M.
    Wedzicha, J.
    Decramer, M.
    Vestbo, J.
    Banerji, D.
    RESPIROLOGY, 2014, 19 : 117 - 117
  • [3] Comparison of COPD Exacerbations With Once-Daily QVA149 Versus Twice-Daily Salmeterol/Fluticasone Combination: The ILLUMINATE Study
    Bateman, Eric
    Vogelmeier, Claus
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [4] COMPARISON OF COPD EXACERBATIONS WITH ONCE-DAILY QVA149 VERSUS TWICE-DAILY SALMETEROL/FLUTICASONE COMBINATION: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E. D.
    Chen, H.
    Banerji, D.
    THORAX, 2013, 68 : A184 - A185
  • [5] Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study
    Vogelmeier, Claus
    Bateman, Eric
    Pallante, John
    Bryant, Hannah
    Alagappan, Vijay
    D'Andrea, Peter
    He, Ellie
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [6] ONCE-DAILY QVA149 PROVIDES SUPERIOR BRONCHODILATION AND IMPROVES LUNG FUNCTION VERSUS TWICE-DAILY FLUTICASONE/SALMETEROL IN COPD PATIENTS: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    He, E.
    Banerji, D.
    THORAX, 2012, 67 : A149 - A149
  • [7] Once-Daily Qva149 Demonstrates Superior Lung Function Compared To Twice-Daily Salmeterol/fluticasone In All Subgroups Of COPD Patients: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [8] Once-Daily Qva149 Improves Breathlessness And Reduces Rescue Medication Use Compared To Twice-Daily Salmeterol/fluticasone In Patients With COPD: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [9] QVA149 SIGNIFICANTLY IMPROVES LUNG FUNCTION AND SYMPTOMS COMPARED TO TWICE-DAILY FLUTICASONE/SALMETEROL IN COPD PATIENTS: THE ILLUMINATE STUDY
    Kurstjens, N. P.
    Frenzel, C.
    Bateman, E.
    Vogelmeier, C.
    Banerji, D.
    RESPIROLOGY, 2013, 18 : 58 - 58
  • [10] Once-Daily Qva149 Is More Effective Than Twice-Daily Salmeterol/fluticasone In Improving Lung Function, In Patients With Severe Chronic Obstructive Pulmonary Disease (COPD): The Illuminate Study
    Vogelmeier, C.
    Bateman, E. D.
    D'Andrea, P.
    Mezzi, K.
    Chen, H.
    Banerji, D.
    Fogel, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
12345